Limitations, agreements, and source contact

Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM) · Source last updated 2017-03-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

true

restrictive Agreement

false

limitations And Caveats

description

This trial was closed early due to slow patient accrual. The planned accrual had been 44.

point Of Contact

email

tawee.tanvetyanon@moffitt.org

organization

H. Lee Moffitt Cancer Center and Research Institute

phone

813-745-3050

title

Tawee Tanvetyanon, M.D.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice